Keros Therapeutics Inc (KROS) Stock Analysis

Keros Therapeutics Inc (KROS) is a publicly traded company in the HEALTHCARE sector. It trades at $10.55, carries a market capitalization of $222.66M. This page summarizes the public market data, fundamentals, and frequently asked questions for KROS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Keros Therapeutics Inc currently has a Bullish sentiment score of 0.17.

About Keros Therapeutics Inc

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Lexington, Massachusetts, dedicated to developing transformative therapies for hematological and musculoskeletal disorders. The company is advancing a proprietary pipeline of drug candidates designed to address significant unmet medical needs in these challenging therapeutic areas. With a strong focus on scientific innovation and comprehensive clinical development, Keros Therapeutics is strategically poise...

GNG Research Analysis

GNG Research scores Keros Therapeutics Inc (KROS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for KROS.

Frequently Asked Questions

Does KROS pay dividends?

Keros Therapeutics Inc (KROS) does not currently pay a regular dividend.

What is KROS's market cap?

Keros Therapeutics Inc (KROS) has a market capitalization of $222.66M with a current stock price of $10.55.